Literature DB >> 12183281

Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae.

Sue E Baum1, Sharon A Crawford, M L McElmeel, Cynthia G Whitney, James H Jorgensen.   

Abstract

The activity of AZD2563 against 250 highly resistant pneumococci and 267 drug-susceptible isolates was determined. The AZD2563 MICs for 50 and 90% of the strains tested were 1 and 2 micro g/ml and 0.5 and 1 micro g/ml, respectively, for the two isolate groups. These MICs were within 1 log(2) dilution of those of linezolid.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12183281      PMCID： PMC127405          DOI： 10.1128/AAC.46.9.3094-3095.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors.

Authors:  M Fines; R Leclercq
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

3.  Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.

Authors:  J D Heffelfinger; S F Dowell; J H Jorgensen; K P Klugman; L R Mabry; D M Musher; J F Plouffe; A Rakowsky; A Schuchat; C G Whitney
Journal:  Arch Intern Med       Date:  2000-05-22

4.  Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Authors:  S Tsiodras; H S Gold; G Sakoulas; G M Eliopoulos; C Wennersten; L Venkataraman; R C Moellering; M J Ferraro
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

5.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

Authors:  C G Whitney; M M Farley; J Hadler; L H Harrison; C Lexau; A Reingold; L Lefkowitz; P R Cieslak; M Cetron; E R Zell; J H Jorgensen; A Schuchat
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

6.  Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.

Authors:  A P Johnson; M Warner; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

7.  Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors.

Authors:  N B Matassova; M V Rodnina; R Endermann; H P Kroll; U Pleiss; H Wild; W Wintermeyer
Journal:  RNA       Date:  1999-07       Impact factor: 4.942

Review 8.  Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid.

Authors:  J F Plouffe
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

9.  In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.

Authors:  R N Jones; S G Jenkins; D J Hoban; M A Pfaller; R Ramphal
Journal:  Diagn Microbiol Infect Dis       Date:  2000-06       Impact factor: 2.803

10.  Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.

Authors:  G V Doern; A B Brueggemann; H Huynh; E Wingert
Journal:  Emerg Infect Dis       Date:  1999 Nov-Dec       Impact factor: 6.883
View more
  1 in total

1.  Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria.

Authors:  Stefan Schwarz; Wanjiang Zhang; Xiang-Dang Du; Henrike Krüger; Andrea T Feßler; Shizhen Ma; Yao Zhu; Congming Wu; Jianzhong Shen; Yang Wang
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.